Drugs / Idetrexed
Idetrexed
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06976892 | Aug 2025 → Dec 2029 expected | malignant ovarian serous tumor | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1 | NCT02360345 | Sep 2013 → Jan 2020 | cancer | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Idetrexed | “Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor".” NCT06976892 ↗ |
| Known as | 6S-BGC-945 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594449 ↗ |
| Known as | BGC-945 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594449 ↗ |
| Known as | CB-300945 (S) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594449 ↗ |
| Known as | ONX-0801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02360345 ↗ |
| Known as | ONX-801 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594449 ↗ |
| Action | Inhibit | “Blocking the action of thymidylate synthase with a drug like Idetrexed” NCT06976892 ↗ |
| Modality | Small molecule | — CHEMBL4594449 ↗ |
| Route | Intravenous | “ONX-0801 will be administered over a 1-hour IV infusion on Days 1, 8, 15 and 22 of repeated 28-day treatment cycles.” NCT02360345 ↗ |